Cochlear shares (ASX: COH) have fallen 6.63% to begin the month at A$130.34, with the stock coming under pressure at the end of a previously strong quarter. Whilst the Cochlear share price ended Q3 with a gain of 14.65%, resistance had been found three times over the past couple of months at A$145, a level that once again preceded this latest move lower.
The stock remains down 50% since the start of 2026, and perhaps more concerning to near term momentum for technical traders, the price fell below both the 30 day and 50 day SMA on the day.
Fundamentals Driving The Stock
Today’s move follows a 60% relief rally over the preceding five months into September 29, with Cochlear moving steadily off a decade low. Since Cochlear cut its FY26 earnings guidance in April, it has been a period of rebuild, yet with Australian inflation running at 4% and the cash rate at a 15-year high of 4.6%, markets appear less willing to pay a premium for long-duration growth.
In April, Cochlear slashed its FY26 underlying net profit guidance from a range of A$435 million to A$460 million down to A$290 million to A$330 million, citing softer trading, order disruption linked to Middle East conflict, margin pressure and restructuring costs. The full-year result in August landed at the top of that revised range, with revenue up 2% in constant currency to about A$2.3 billion and underlying net profit of A$322 million. That was still roughly 20% below the original plan, and margins remain well short of the company’s 18% target, even as cash flow improved sharply.
The Nexa implant platform, now more than 95% of developed-market volume with an average price lift of about 3%, was meant to restore momentum. Instead, registration and contracting processes ran longer than expected in markets where Cochlear pushed for higher prices, delaying the earnings benefit. Layered on top is a class action, filed in late September, alleging investors were misled by the original 2026 profit forecast before it was cut. Cochlear has said it will defend the claim, but the litigation keeps the April downgrade, and the disclosure questions around it, in front of the market.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
What Lay Ahead
Looking to the analyst community for clues, and the average price target at A$140.07 is in the resistance zone. The technical setup, with a near term triple top, and with the share price trading below the 50-day moving average near A$133.47, and the 50-day well below the 200-day ~ A$160, points to the bear side. Today’s fall also pushed the price through the lower Bollinger band around A$131.21, with the move stretching beyond its recent trading range. The 20-day CCI has cooled to about 34, neutral territory after an earlier upside stretch, which fits a market steadily unwinding optimism built up around the Nexa launch.
After a period of steady bullish momentum off lows that had seen COH shares add 60% in five months, resistance has been found stubborn around A$145, and it may take a fundamental update in order to continue the rally. With the stock trading 50% lower on the year after today’s move, there may be some who are looking to take some risk off the table in amongst a broadly red tape, with the ASX 200 fall back 1.99% to start the month.
So what does Q4 hold in store? After a punishing Q1 that saw shares fall 35.21% and a Q2 that delivered more of the same (-28%), bulls will be looking to avoid a return to selling. Reclaiming the 50 day SMA at A$133.47 would be the first meaningful target, yet the macro backdrop may prove pivotal.
